Global Codeine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030Codeine is an opiate used to treat pain, coughing, and diarrhea. It is typically used to treat mild to moderate degrees of pain. The global Codeine market size was valued at US$ 264 million in 2023 and is forecast to a readjusted size of USD 180 million by 2030 with a CAGR of -5.4% during review period. Market competition is intense. Taiji, Mallinckrodt, TEVA, Johnson & Johnson, Medreich, Sanofi Aventis, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. For the major company of Codeine, Taiji and Mallinckrodt accounted for about 16% market share respectively in recent years. This report is a detailed and comprehensive analysis for global Codeine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Ingredient and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key...Read more | USD 3,480.00 |
Global Anti-Venom Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. The global Anti-Venom market size was valued at US$ 1032 million in 2023 and is forecast to a readjusted size of USD 1363 million by 2030 with a CAGR of 4.1% during review period. CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global...Read more | USD 3,480.00 |
Global Hydroxyproline Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030Hydroxyproline (HYP) is one of the amino acids, which is a kind of non-essential amino acid. It is one of the main components of collagen tissue and a characteristic amino acid in collagen, accounting for about 13% of the total collagen amino acids. The global Hydroxyproline market size was valued at US$ 79 million in 2023 and is forecast to a readjusted size of USD 118 million by 2030 with a CAGR of 6.0% during review period. The industry"s leading producers are Kyowa Hakko, Evonik and Jinyang Pharmaceutical, which accounted for 20.06%, 9.18% and 10.54% of revenue in 2019, respectively. This report is a detailed and comprehensive analysis for global Hydroxyproline market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing...Read more | USD 3,480.00 |
Global Medical Device Outsourcing Market 2024 by Company, Regions, Type and Application, Forecast to 2030Medical devices outsourcing is the practice of hiring a third party for different business purposes such as manufacturing, supply chain management, prototyping, and product designing. They help the OEM to decrease their production time and labor cost. Outsourcing of medical devices is comparatively a new concept to concentrate on the core skills of the business, such as technological and clinical advances. They have the ability to provide different services such as regulatory affair services, product testing, product maintenance services, product design & development, product maintenance services, and contract manufacturing. The global Medical Device Outsourcing market size was valued at US$ 84410 million in 2023 and is forecast to a readjusted size of USD 157960 million by 2030 with a CAGR of 9.5% during review period. Major producers in the sector include Cardinal Health Inc., Jabil and Heraeus Holding GmbH, which accounted for 15.52%, 9.03% and 8.17% of revenue...Read more | USD 3,480.00 |
Global Cefotaxime Sodium API Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030Cefotaxime sodium is the sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria. The global Cefotaxime Sodium API market size was valued at US$ 103 million in 2023 and is forecast to a readjusted size of USD 98 million by 2030 with a CAGR of -0.8% during review period. Market competition is intense. REYOUNG, Nectar Lifesciences, Medya Pharma, Sandoz, Kelun, etc. are the leaders of the industry,...Read more | USD 3,480.00 |